R R

What Is Ozanimod?

Ozanimod is a prescription immunomodulating medication marketed under the brand name Zeposia. It belongs to the sphingosine 1-phosphate receptor modulator class and is approved for certain relapsing forms of multiple sclerosis and moderately to severely active ulcerative colitis in adults. Ozanimod is taken orally once daily after an initial dose escalation period. It changes how certain immune cells circulate through the body, helping reduce inflammation. Ozanimod does not cure multiple sclerosis or ulcerative colitis and requires medical assessment before treatment begins.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Ozanimod?

Ozanimod is a prescription immunomodulating medication marketed under the brand name Zeposia. It belongs to the sphingosine 1-phosphate receptor modulator class and is approved for certain relapsing forms of multiple sclerosis and moderately to severely active ulcerative colitis in adults. Ozanimod is taken orally once daily after an initial dose escalation period. It changes how certain immune cells circulate through the body, helping reduce inflammation. Ozanimod does not cure multiple sclerosis or ulcerative colitis and requires medical assessment before treatment begins.

read more about ozanimod ...

Copy this HTML:

Copy HTML Copied!

How Does Ozanimod Work?

Ozanimod binds to sphingosine 1-phosphate receptor subtypes 1 and 5. Its effects on S1P1 receptors cause certain lymphocytes to remain within lymphoid tissues, reducing the number of circulating immune cells that can contribute to inflammation. In multiple sclerosis, this can reduce immune activity associated with damage to the central nervous system. In ulcerative colitis, it can reduce inflammatory activity affecting the colon. Ozanimod does not directly repair nerve damage or permanently eliminate intestinal inflammation. Lower circulating lymphocyte levels can also increase susceptibility to infections.

What Conditions Does Ozanimod Treat?

Ozanimod is approved for relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis. It is also approved for moderately to severely active ulcerative colitis in adults. A clinician evaluates disease activity, previous treatments, infection history, cardiac health, liver function, and eye health before starting therapy. Ozanimod is not approved for primary progressive multiple sclerosis or every type of inflammatory bowel disease. Certain heart conditions and medication interactions can prevent safe use.

How Should Ozanimod Be Taken?

Ozanimod treatment begins with a seven-day dose escalation to reduce the risk of heart rate changes. Patients take 0.23 mg once daily on days one through four, followed by 0.46 mg once daily on days five through seven. From day eight onward, the standard maintenance dose is 0.92 mg once daily. Patients with mild to moderate liver impairment follow a modified maintenance schedule. Capsules are swallowed whole, with or without food. Before treatment, clinicians review heart rhythm, blood counts, liver function, medication interactions, vaccination history, and eye examination needs. Certain treatment interruptions require restarting the dose escalation schedule.

What Are the Side Effects and Warnings of Ozanimod?

Common adverse effects include upper respiratory infections, elevated liver enzymes, headache, and increased blood pressure. Serious risks include infections, slowed heart rate or conduction abnormalities, liver injury, macular edema, and progressive multifocal leukoencephalopathy, a rare serious brain infection. Ozanimod can also cause respiratory effects and fetal harm. Patients with diabetes or a history of uveitis require particular attention to macular edema risk. New blurred vision, eye pain, neurological changes, severe infections, or jaundice require prompt medical assessment. Certain live vaccines should be avoided during treatment and for three months afterward.

Common Questions About Ozanimod

Is ozanimod the same as Zeposia?

Yes. Zeposia is the brand name for ozanimod, an oral sphingosine 1-phosphate receptor modulator.

Can ozanimod treat ulcerative colitis?

Yes. Ozanimod is approved for adults with moderately to severely active ulcerative colitis. It helps reduce inflammatory activity and can support clinical remission in eligible patients.

How often is ozanimod taken?

Ozanimod is taken once daily after a seven-day dose escalation. The standard maintenance dose is 0.92 mg daily, with modified instructions for certain patients.

Can ozanimod affect eyesight?

Yes. Ozanimod can cause macular edema, which may produce blurred or distorted vision. Eye examinations are recommended in specified situations, and new visual symptoms require prompt evaluation.

References

DailyMed - ZEPOSIA (ozanimod) capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93ce2fab-edfb-4804-8074-963071de51e4. Date Accessed October 30, 2026.

Ozanimod. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK572853/. Date Accessed October 30, 2026.

Ozanimod. MedlinePlus. https://medlineplus.gov/druginfo/meds/a620029.html. Date Accessed October 30, 2026.

Ozanimod. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Ozanimod. Date Accessed October 30, 2026.

Zeposia. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia. Date Accessed October 30, 2026.